Free Trial
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Price, News & Analysis

Intellia Therapeutics logo
$11.24 +0.99 (+9.65%)
As of 11:20 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Intellia Therapeutics Stock (NASDAQ:NTLA)

Key Stats

Today's Range
$10.32
$11.06
50-Day Range
$6.99
$10.73
52-Week Range
$5.90
$28.18
Volume
1.94 million shs
Average Volume
2.98 million shs
Market Capitalization
$1.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.37
Consensus Rating
Moderate Buy

Company Overview

Intellia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

NTLA MarketRank™: 

Intellia Therapeutics scored higher than 94% of companies evaluated by MarketBeat, and ranked 65th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 12 buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Intellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Intellia Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.07) to ($5.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intellia Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intellia Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intellia Therapeutics has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Intellia Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    29.58% of the float of Intellia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Intellia Therapeutics has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Intellia Therapeutics has recently decreased by 5.93%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Intellia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Intellia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    29.58% of the float of Intellia Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Intellia Therapeutics has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Intellia Therapeutics has recently decreased by 5.93%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Intellia Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Intellia Therapeutics this week, compared to 12 articles on an average week.
  • Search Interest

    Only 24 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.
  • MarketBeat Follows

    Only 9 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,472.00 in company stock.

  • Percentage Held by Insiders

    Only 3.10% of the stock of Intellia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intellia Therapeutics' insider trading history.
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NTLA Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
NTLA - Intellia Therapeutics Inc Chart - Morningstar
Intellia Therapeutics, Inc. (NTLA) - Yahoo Finance
See More Headlines

NTLA Stock Analysis - Frequently Asked Questions

Intellia Therapeutics' stock was trading at $11.66 at the start of the year. Since then, NTLA stock has decreased by 12.1% and is now trading at $10.25.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The firm's revenue for the quarter was down 42.6% on a year-over-year basis.
Read the conference call transcript
.

Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW).

Company Calendar

Last Earnings
5/08/2025
Today
7/08/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.37
High Stock Price Target
$68.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+207.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$519.02 million
Net Margins
-1,154.10%
Pretax Margin
-1,154.10%

Debt

Sales & Book Value

Annual Sales
$57.88 million
Price / Cash Flow
N/A
Book Value
$8.56 per share
Price / Book
1.27

Miscellaneous

Free Float
100,372,000
Market Cap
$1.13 billion
Optionable
Optionable
Beta
2.21

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NTLA) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners